Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792296 | 0.98 | ACHE (0.48) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL686372 | 0.91 | IDO1 (0.52) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL25922472 | 0.89 | DAO (0.42) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL15429373 | 0.87 | ACHE (0.61) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| Ammonia Solution, Strong SCHEMBL5998797 | 0.87 | ROCK2 (0.41) | HDAC4HDAC7HDAC5IDO1TDO2 | |
| SCHEMBL16191280 | 0.86 | ACHE (0.48) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| Ammonia Solution, Strong SCHEMBL5998612 | 0.84 | TBXAS1 (0.43) | SLC6A2SLC6A4 | |
| SCHEMBL179253 | 0.83 | ACHE (0.48) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| Ammonia Solution, Strong SCHEMBL6001272 | 0.82 | AOC3 (0.45) | ACHEHDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL23565933 | 0.81 | TBXAS1 (0.43) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | ACHE 248/4885HDAC4 975/4885HDAC7 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.